Clinical response and tolerability of fampridine in clinical practice. (April 2016)

• Record Type: Journal Article
• Authors: Costa-Arpín, Eva; Pato, Antonio; Rodríguez-Regal, Ana; Midaglia, Luciana; Yáñez, Rosa; Muñoz, Delicias; Lorenzo, José R; Amigo, Campo; Prieto, José M
• Is Part Of: Neurodegenerative disease management. Volume 6:Number 2(2016)
• Page Start: 99
• Page End: 105
• Publication Date: 2016-04
• Subjects: efficacy -- gait disorder -- multiple sclerosis -- prolonged-release fampridine -- safety; Nervous system -- Degeneration -- Periodicals; 616.8
• DOI: 10.2217/nmt-2015-0004
• Languages: English
• ISSNs: 1758-2024

Abstract

Background: Gait disorder is very prevalent in multiple sclerosis. After 15 years of disease progression, 50% of patients need assistive devices for walking.Materials & methods: We performed a multicenter observational study, including multiple sclerosis patients with an Expanded Disability Status Scale score between 4.0 and 7.0, normal kidney function and no previous history of seizures.Results: The study sample comprised 138 patients with average age of 50.3 years median Expanded Disability Status Scale of 6.0. After treatment, a significant reduction was observed in both the Timed 25-Foot Walk test (baseline, 20.3 s; 14 days, 13.2 s; p < 0.001; 3 months, 12.1 s; p < 0.001) and the 12-Item Multiple Sclerosis Walking Scale score (baseline, 82.3; 14 days, 59.4; p < 0.001; 3 months, 57.2; p < 0.001). Adverse events were recorded in 39.9% of patients.